Lyka Labs Ltd (LYKALABS) is currently trading at 83.13 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products. The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India. Post-2016, Lyka merged its subsidiaries, bolstering its focus on domestic markets and ethical products. Significant equity acquisition by IPCA and partners in 2021-22 established them as joint promoters, signaling strategic alignment. In 2023, Lyka acquired the animal healthcare business of Agilis Healthcare, enhancing its veterinary portfolio.

Over the past 52 weeks, Lyka Labs Ltd has traded between a low of ₹44.49 and a high of ₹104.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Lyka Labs Ltd has a market capitalization of approximately 294.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Lyka Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -31.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 294.64 Cr, Lyka Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Lyka Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Lyka Labs Ltd is -31.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone revenue from operations was ₹42.3094 crore and standalone net profit was reported at ₹2.1001 crore; export revenues rose 68.03% to ₹14.8342 crore.

Lyka Labs’ 47th AGM is scheduled for Monday, 10 August 2026 at 12:30 PM (IST).